|
Real-time Estimate
Cboe BZX
10:07:18 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 2.195 USD | -0.23% |
|
-14.45% | -39.34% |
Company Valuation: Altimmune, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 363.1 | 808.4 | 604.4 | 512.8 | 394 | 427.9 | - | - |
| Change | - | 122.62% | -25.23% | -15.16% | -23.16% | 8.6% | - | - |
| Enterprise Value (EV) 1 | 363.1 | 697.3 | 469.3 | 380.9 | 350.2 | -12.56 | 96.24 | 257.7 |
| Change | - | 92.02% | -32.7% | -18.84% | -8.04% | -103.59% | 866.17% | 167.81% |
| P/E | -3.9x | -9.09x | -6.78x | -5.38x | -3.61x | -3.78x | -3.46x | -3.35x |
| PBR | - | - | - | 4.22x | - | - | - | - |
| PEG | - | 0.4x | 0.82x | 0.3x | 0.1x | 0.1x | -0.38x | -0.99x |
| Capitalization / Revenue | 82.3x | -11,889x | 1,419x | 25,640x | 9,611x | - | - | 167x |
| EV / Revenue | 82.3x | -10,255x | 1,102x | 19,044x | 8,543x | - | - | 101x |
| EV / EBITDA | -3.77x | -7.93x | -4.92x | -3.7x | -3.71x | 0.11x | -0.72x | -1.65x |
| EV / EBIT | -4.25x | -7.95x | -5.62x | -3.69x | -3.71x | 0.11x | -0.74x | -1.85x |
| EV / FCF | -4.02x | -11.1x | -6.19x | -4.77x | -5.19x | 0.14x | -0.91x | -1.82x |
| FCF Yield | -24.9% | -8.99% | -16.2% | -21% | -19.3% | 710% | -110% | -55.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.35 | -1.81 | -1.66 | -1.34 | -1 | -0.582 | -0.6356 | -0.6571 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.41 | -0.068 | 0.426 | 0.02 | 0.041 | - | - | 2.562 |
| EBITDA 1 | -96.36 | -87.94 | -95.45 | -102.9 | -94.48 | -112.1 | -133.2 | -156.6 |
| EBIT 1 | -85.54 | -87.74 | -83.51 | -103.2 | -94.49 | -110.2 | -129.4 | -139.1 |
| Net income 1 | -97.09 | -84.71 | -88.45 | -95.06 | -88.09 | -99.55 | -116.8 | -138.6 |
| Net Debt 1 | - | -111.1 | -135.2 | -131.9 | -43.8 | -440.5 | -331.7 | -170.2 |
| Reference price 2 | 9.160 | 16.450 | 11.250 | 7.210 | 3.610 | 2.200 | 2.200 | 2.200 |
| Nbr of stocks (in thousands) | 39,644 | 49,146 | 53,729 | 71,125 | 109,155 | 194,518 | - | - |
| Announcement Date | 3/15/22 | 2/28/23 | 3/27/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.78x | - | 0.11x | - | 428M | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 23.12x | 26.57x | 13.80x | 0.32% | 37.28B | |
| Weighted average by Cap. | 25.93x | 25.01x | 15.46x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALT Stock
- Valuation Altimmune, Inc.
Select your edition
All financial news and data tailored to specific country editions
